Lilly to Acquire Bowel Disease Drug Maker Morphic for $3.2 Billion
- July 12, 2024
Eli Lilly & Co. is buying Waltham, MA-based Morphic Holding, Inc. for roughly $3.2 billion in a move aimed at expanding its immunology pipeline with oral integrin therapies, including for inflammatory bowel disease (IBD), the companies announced July 8.
ARTICLE TAGS
You must be logged in to access this content.